<DOC>
	<DOCNO>NCT02539303</DOCNO>
	<brief_summary>This feasibility pilot study evaluate impact local delivery Yamani-15/5 ( combination L-Lactic acid 15 % D-Gluconic acid 5 % ) vascular calcification low extremity patient severe peripheral arterial disease ( PAD ) deem unreconstructable arterial disease already schedule undergo limb amputation ( knee knee amputation ) .</brief_summary>
	<brief_title>Delivery Yamani-15/5 Chemical Solution PAD</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Subject severe calcific PAD deem unreconstructable arterial disease already schedule undergo limb amputation ( knee knee amputation ) . Exclusion : Patients undergo amputation limb infection , osteomyelitis cancer . Patients chronic kidney disease stage V ( unless dialysis ) . Patients liver cirrhosis . Patients history deep vein thrombosis pulmonary embolization last 3 month . Patients history stroke last 3 month . Patients unstable angina history myocardial infarction last 3 month . Patients sepsis , respiratory failure , hypovolemic shock cardiogenic shock . Women pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>